MetaCap

GeneDx Holdings Corp. Class A (WGS)

NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD

45.46-3.78 (-7.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

WGS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.76
52-week range
32.21 – 170.87
Day range
45.16 – 49.10
Volume / Avg
912.39K / 869.34K
Beta
—

52-week range

$32.21$170.87

WGS stock today

GeneDx (WGS) closed at $45.46 on Nov 20, down 7.68% (-$3.78), versus the S&P 500's 3.70% decline. Shares are 73.4% below their 52-week high of $170.87, set on Dec 2, 2025 and 41.1% above the 52-week low of $32.21, near the bottom of the past year's range. WGS is down 65.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.0%.

GeneDx has posted a net loss over the last twelve months (EPS of -$3.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About GeneDx

Company profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

Industry
Medical/Nursing Services
CEO
Ms. Katherine A. Stueland
Headquarters
Stamford, CT
Employees
1,300
IPO year
2020
Website
genedx.com

Financial highlights

Full financials

In fiscal 2025, GeneDx generated $427.5 million in revenue, up 40.0% from fiscal 2024, its 2nd consecutive year of revenue growth. GeneDx reported a net loss of $21.0 million, compared with a loss of $52.3 million a year earlier. Gross margin was 69.7% (up from 63.6%) and operating margin -3.1%.

GeneDx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$427.54M$305.45M$202.57M$234.69M$212.19M
Growth+39.97%+50.79%-13.69%+10.60%+18.33%
Net income$-21.02M$-52.29M$-175.77M$-548.98M$-245.39M
EPS (diluted)$-0.73$-1.94$-7.23$-53.63$-2.27

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$82.00+80.38%

  • Strong buy 1
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $65.00High $102.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$0.49 vs $0.07
Surprise
+600.00%

WGS news

All WGS news

GeneDx peers

Health Care sector
WGS peer companies
CompanyPrice% ChgMarket capCompare
TDOCTeladoc Health Inc.7.45-4.36%$1.36Bvs WGS
USPHU.S. Physical Therapy Inc.95.93+1.71%$1.43Bvs WGS
INNVInnovAge Holding Corp.9.16+2.81%$1.25Bvs WGS
PNTGThe Pennant Group Inc.34.64+1.61%$1.22Bvs WGS
AHCOAdaptHealth Corp.7.20-0.69%$982.98Mvs WGS
OMDAOmada Health Inc.11.87-5.04%$736.39Mvs WGS
SBCSBC Medical Group Holdings Incorporated5.17-7.68%$530.32Mvs WGS
ADUSAddus HomeCare Corporation122.50+1.18%$2.28Bvs WGS

Indexes, lists and sector

GeneDx stock FAQ

What is GeneDx's stock price today?

WGS last traded at $45.46 as of Nov 20, 4:00 PM EST, down 7.68% on the day. Prices are delayed at least 15 minutes.

Does GeneDx pay a dividend?

No. GeneDx does not currently pay a regular cash dividend.

Who is GeneDx's CEO?

Ms. Katherine A. Stueland is the chief executive officer of GeneDx Holdings Corp. Class A, which has about 1,300 employees.

Has WGS ever split its stock?

Yes. The most recent WGS stock split was a 1-for-33 split on May 4, 2023.

What is the WGS 52-week high?

The 52-week high for WGS is $170.87 and the 52-week low is $32.21. The stock is currently 73.4% below its high.

Compare WGS